These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17417659)

  • 1. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review.
    Franchini M; Veneri D; Lippi G
    Bone Marrow Transplant; 2007 Jun; 39(12):729-35. PubMed ID: 17417659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
    Grounds RM; Bolan C
    Crit Care; 2005; 9 Suppl 5(Suppl 5):S29-36. PubMed ID: 16221317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidotes to haemorrhage: recombinant factor VIIa.
    Kessler CM
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Off-license" use of recombinant activated factor VII.
    Ghorashian S; Hunt BJ
    Blood Rev; 2004 Dec; 18(4):245-59. PubMed ID: 15501553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
    Franchini M; Manzato F; Salvagno GL; Lippi G
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):589-93. PubMed ID: 17890943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients.
    Ng HJ; Lee LH
    Vasc Health Risk Manag; 2006; 2(4):433-40. PubMed ID: 17323597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
    Abshire TC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
    Mathew P
    Thromb Haemost; 2004 Oct; 92(4):738-46. PubMed ID: 15467904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
    Blatt J; Gold SH; Wiley JM; Monahan PE; Cooper HC; Harvey D
    Bone Marrow Transplant; 2001 Aug; 28(4):405-7. PubMed ID: 11571515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
    Mohr AM; Holcomb JB; Dutton RP; Duranteau J
    Crit Care; 2005; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of recombinant activated factor VII in platelet-associated bleeding.
    Franchini M; Lippi G; Guidi GC
    Hematology; 2008 Feb; 13(1):41-5. PubMed ID: 18534065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
    Martinowitz U; Michaelson M;
    J Thromb Haemost; 2005 Apr; 3(4):640-8. PubMed ID: 15842347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
    Martinowitz U; Kenet G; Segal E; Luboshitz J; Lubetsky A; Ingerslev J; Lynn M
    J Trauma; 2001 Sep; 51(3):431-8; discussion 438-9. PubMed ID: 11535886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.